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Modelling the impact and cost-effectiveness of
combination prevention amongst HIV serodiscordant
couples in Nigeria
Kate M. Mitchella, Aure´lia Le´pinea, Fern Terris-Prestholta,
Kwasi Torpeyb, Hadiza Khamofub, Morenike O. Folayanc, Jonah Musad,
James Anenihe, Atiene S. Sagayd, Emmanuel Alhassane,
John Idokoe and Peter Vickermanf
Objective: To estimate the impact and cost-effectiveness of treatment as prevention
(TasP), pre-exposure prophylaxis (PrEP) and condom promotion for serodiscordant
couples in Nigeria.
Design: Mathematical and cost modelling.
Methods: A deterministic model of HIV-1 transmission within a cohort of serodiscor-
dant couples and to/from external partners was parameterized using data from Nigeria
and other African settings. The impact and cost-effectiveness were estimated for
condom promotion, PrEP and/or TasP, compared with a baseline where antiretroviral
therapy (ART) was offered according to 2010 national guidelines (CD4þ <350 cells/ml)
to all HIV-positive partners. The impact was additionally compared with a baseline of
current ART coverage (35% of those with CD4þ<350 cells/ml). Full costs (in US $2012)
of programme introduction and implementation were estimated from a provider
perspective.
Results: Substantial benefits came from scaling up ART to all HIV-positive partners
according to 2010 national guidelines, with additional smaller benefits of providing
TasP, PrEP or condom promotion. Compared with a baseline of offering ART to all HIV-
positive partners at the 2010 national guidelines, condom promotion was the most cost-
effective strategy [US $1206/disability-adjusted-life-year (DALY)], the next most cost-
effective intervention was to additionally give TasP to HIV-positive partners (incre-
mental cost-effectiveness ratio US $1607/DALY), followed by additionally giving PrEP
to HIV-negative partners until their HIV-positive partners initiate ART (US $7870/
DALY). When impact was measured in terms of infections averted, PrEP with condom
promotion prevented double the number of infections as condom promotion alone.
Conclusions: The first priority intervention for serodiscordant couples in Nigeria should
be scaled up ART access for HIV-positive partners. Subsequent incremental benefits are
greatest with condom promotion and TasP, followed by PrEP.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Although HIV incidence in Nigeria declined by more than
50% between 2001 and 2012, it remains the second-largest
epidemic in theworld, with 3.4 million people infected [1].
Only an estimated 35% of those eligible for antiretroviral
therapy (ART) in Nigeria currently receive it [1].
Previous modelling for Nigeria using the Joint United
Nations Programme on HIV and AIDS (UNAIDS)
modes of transmission model estimated that a large
proportion (26–46%) of new HIV infections occur
among couples in stable relationships [2]. Efforts are being
stepped up to identify those in serodiscordant partner-
ships, by testing the male partners, as well as the women
attending antenatal care (ANC) for HIV [3].
Trials have demonstrated that pre-exposure prophylaxis
(PrEP) [4] and treatment as prevention (TasP) [5] can
substantially reduce transmission within serodiscordant
partnerships. The Partners PrEP trial found that daily PrEP
for HIV-negative partners in heterosexual serodiscordant
couples reduced incidence by 67–75% [4]. Other studies
giving PrEP to HIV-negative heterosexuals (not restricted
to those in serodiscordant partnerships) have had mixed
results, with PrEP effectiveness driven by medication
adherence [6]. The HIV Prevention Trials Network
(HTPN) 052 trial found that TasP – giving ART
immediately to the HIV-positive partner, rather than
waiting until they reached the recommended CD4þ
threshold to initiate ART – reduced transmission within
serodiscordant partnerships by 96% [5]. Prospective studies
have found lower protection levels in real-world settings
[7].
Several studies have found that people increase condom
use once they discover they are in an HIV-serodiscordant
relationship [8–10], with this increase happening soon
after diagnosis [8,9]. Additional increases in condom use
by serodiscordant couples have been reported following
couples [9] and male-focused [10] HIV testing and
counselling, with very high condom use reported by
serodiscordant couples in HIV-prevention trials [4,5,11].
There is increasing interest in measuring the impact of
combinations of prevention tools on HIV incidence, with
mathematical modelling playing a key role in guiding
policy makers by providing estimates of the combined
impact of different interventions. Several models have been
used to estimate the impact and cost-effectiveness of
combination HIV prevention in South Africa [12,13], but
these findings cannot easily be extrapolated to Nigeria,
which has higher male circumcision rates, lower HIV
prevalence, and lower per-capita wealth than South Africa.
The present study aimed to estimate the impact and cost-
effectiveness of PrEP, TasP and condom promotion for
serodiscordant couples in Nigeria.
Methods
We developed a mathematical model describing HIV-1
transmission within serodiscordant heterosexual partner-
ships and to/from external sexual partners. This model
was parameterized with behavioural, biological and cost
data from Nigeria and elsewhere, and used to estimate the
impact and cost-effectiveness of the interventions among
serodiscordant couples already identified through ANC.
Transmission model
The model is a deterministic, compartmental cohort
model, dividing HIV-negative people by PrEP status,
HIV-positive people by CD4þ cell count (>350 cells/ml,
200–350 cells/ml, <200 cells/ml) and ART status (naı¨ve,
on ART, post-ART), and couples by whether they are
receiving condom promotion. PrEP and condom
promotion are assumed to be initiated at the beginning,
whereas ART can also be initiated later, at a rate reflecting
eligibility, CD4þ-testing frequency and ARTacceptance.
Those refusing or dropping out of ART enter the post-
ART group and, assuming they only seek treatment upon
becoming symptomatic, only (re-)initiate ART with
CD4þ below 200 cells/ml. HIV-negative people are
assumed to stop taking PrEP due to dropout, acquiring
infection or (for some interventions) their partner starting
ART. Couples receiving condom promotion have higher
within-partnership condom use, but the same rates of
condom use with external partners, as couples not
receiving it. Conservatively, within-partnership condom
use falls to non-intervention levels when couples drop out
of condom promotion. HIV-negative partners acquire
HIV either from their HIV-positive partner or from
external partners, at a rate dependent upon frequency of
sex, condom, ART and PrEP use, and CD4þ cell count.
All newly infected individuals have an initial CD4þ cell
count above 350 cells/ml. CD4þ cell counts decline
amongst HIV-positive people off ART, and increase on
ART. Further details and equations are in supplement 1
(http://links.lww.com/QAD/A745).
Transmission model parameters
All of the parameters are defined in Table 1, with data
sources in Table S1 (http://links.lww.com/QAD/A745).
Death rates and CD4þ transition probabilities by CD4þ
cell count and ART status were estimated from data from
other African countries, with additional data from Europe
informing on ART estimates. Age and sex-specific non-
HIV-related death rates were estimated from WHO life-
tables. All rates were converted to monthly probabilities.
Data on sexual behaviour, CD4þ cell counts at diagnosis,
discordant couple characteristics and HIV testing came
from Nigerian studies [14,15].
Condom use by serodiscordant couples, with and without
condom promotion, and ART acceptance rates were
estimated from studies conducted elsewhere in Africa.
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Rates of ART dropout were taken from Nigerian studies
[16,17], dropout rates from condom promotion and pre-
ART care were informed by data from elsewhere in
Africa, and PrEP dropout was informed by dropout rates
in PrEP trials. The efficacy of PrEP, ART, male
circumcision and condoms in reducing HIV transmission
came from published trials and meta-analyses.
Cost model
Full costs (in US $2012) of programme introduction and
implementation were estimated from a provider perspect-
ive and computed from costing studies conducted in
Nigeria [18,19] and elsewhere. For PrEP and ART, total
costs include start-up costs (training and mass media
campaigns), drug, laboratory tests and logistics, and
facility delivery costs. Facility delivery costs take into
account the number of visits patients make to healthcare
facilities (including additional visits early on), and the
duration and staff salary costs for each visit. ART costs
include the costs of treating opportunistic infections. The
costs of identifying serodiscordant couples are not
included. Costs were calculated per person per year for
PrEP and ART, and per couple per year for condom
promotion. For further details see supplement 1 (http://
links.lww.com/QAD/A745).
Intervention scenarios
The main baseline scenario was offering ARTat the 2010
national guidelines (CD4þ <350 cells/ml) to all HIV-
positive partners in serodiscordant couples. An additional
baseline used for the impact analysis only assumed current
ART coverage levels (35%) amongst eligible HIV-
positive partners.
The intervention scenarios considered (in addition to the
baseline offering ARTat CD4þ<350 cells/ml to all HIV-
positive partners) were: TasP (offering ART to all HIV-
positive partners); short-term PrEP (offering PrEP to
HIV-negative partners whose HIV-positive partner is not
on ART, ceasing when their HIV-positive partner
initiates ART or they contract HIV); long-term PrEP
(offering PrEP to all HIV-negative partners, ceasing when
they contract HIV); condom promotion and all
combinations of these. For PrEP scenarios, we assumed
60% of HIV-negative partners accept and start using PrEP.
We assumed 80% of couples begin the condom
promotion programme when offered.
Model calibration and analysis
Latin hypercube sampling [20] was used to sample all
biological, behavioural and cost parameters from their
ranges (Table 1) 2000 times. All parameters were
uniformly distributed apart from ARTefficacy (triangular
distribution).
The model was run for 2 years without ARTusing each of
these 2000 parameter combinations in turn; those giving
an average incidence among HIV-negative partners
between 2 and 9 new infections per 100 person-years
were retained for subsequent analyses. This range reflects
low HIV incidence in serodiscordant couples in clinical
trials [5] up to higher rates seen in cohorts in Zambia and
Uganda [21,22]. All retained parameter sets were run for
20 years, for each baseline scenario and each combination
of interventions.
The impact of each intervention scenario was estimated
in comparison with each of the baseline scenarios in terms
of infections averted, percentage infections averted or
disability-adjusted life-years (DALYs) averted, amongst
members of both the serodiscordant couple cohort and
the pool of external partners, over 20 years. DALYs were
calculated by summing up person-years spent in different
CD4þ and ART categories, weighted with values from
the 2010 Global Burden of Disease study. Incremental
costs associated with each intervention were estimated in
comparison to the baseline scenario (with ARToffered to
all eligible HIV-positive partners). Cost-effectiveness was
calculated as the incremental cost per infection or DALY
averted over 20 years. Both impacts and costs were
discounted into the future at a rate of 10% per year in the
main analysis, accounting for the high preference for the
present observed in Nigeria [23–26]. Uncertainty in
predicted impacts were summarized using 95% credible
intervals (CrIs), which bound the central 95% of impacts
obtained across all parameter combinations. Analysis of
co-variance (ANCOVA) was used to identify which
parameters most influenced intervention impact and cost.
The median incremental cost and impact of each
intervention combination were plotted to identify the
efficiency frontier, which joins the incrementally most
cost-effective interventions as resources increase. The
cost-effectiveness thresholds used were 1 gross domestic
product (GDP) (US $2742) [27] and 3 GDP (US
$8226) per DALY averted for highly cost-effective and
cost-effective interventions, respectively.
In sensitivity analyses, alternative discount rates (3%,
15%), time horizons (10 years, full cohort lifetime),
acceptance rates for PrEP (40%, 80%) and condom
promotion (40%, 60%), and higher rates of ART re-
initiation for HIV-positive members of serodiscordant
couples (same treatment CD4þ criteria and 50%,100%
rate of ART-naive) were also investigated.
Results
Selected parameter sets
Of 2000 parameter combinations investigated, 1103 gave
HIV incidence amongst HIV-negative partners between
2 and 9 per 100 person-years over the first 2 years (median
incidence 5/100 person-years). These parameter com-
binations were used for all subsequent analyses. A median
2038 AIDS 2015, Vol 29 No 15
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0.2% of infections came from external partners (range
0.02–2.4%).
Impact
Compared with current antiretroviral therapy coverage
Compared with the present ART coverage (35% of those
eligible), offering ART to all eligible (CD4þ <350 cells/
ml) HIV-positive partners in serodiscordant couples
averted 15% of all infections over 20 years. This equated
to 35% of the infections averted under the strategy with
the greatest impact (TasP, long-term PrEP and condom
promotion), and 73% of the DALYs (Fig. 1).
Compared with 2010 national treatment guidelines
baseline
Compared with a baseline scenario where all HIV-
positive partners in serodiscordant couples were offered
ART once they reached a CD4þ cell count below
350 cells/ml, the relative impact of each intervention
differed by impact measure (Fig. 2). Long-term PrEP
averted the greatest proportion of remaining infections
(15%), followed by condom promotion (11%), short-
term PrEP (10%) and TasP (10%) (Fig. 2a). In terms of
DALYs averted, TasP had the greatest impact, followed by
long-term PrEP, short-term PrEP and condom pro-
motion (Fig. 2b). The greatest impact using either
measure was achieved with a combination of TasP, long-
term PrEP and condom promotion, which averted 30%
of infections (95% CrI 20–50%), and 356 DALYs (95%
CrI 213–565).
Influential parameters
The parameters most influencing the impact were
frequency of sex within serodiscordant partnerships,
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Fig. 1. Impact compared with current ART coverage (35% of those with CD4R below 350 cells/ml), for all intervention
combinations considered. Impact is measured in terms of (a) infections averted, (b) DALYs averted. Error bars are 95% credible
intervals from 1103 simulations. ART, antiretroviral therapy; DALYs, disability-adjusted life-years; PrEP, pre-exposure prophylaxis.
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
per-sex-act transmission probability, intervention efficacy
and dropout rates (supplement 1, http://links.lww.com/
QAD/A745). Cost estimates were most influenced by
intervention dropout rates and yearly per-person inter-
vention costs.
Cost-effectiveness
Cost-effectiveness was only estimated in comparison with
a baseline scenario where all HIV-positive partners in
serodiscordant couples were offered ART at CD4þ cell
counts below 350 cells/ml. For impact on infections
averted, Fig. 3a suggests that as more resources become
available, after giving ART to HIV-positive partners with
CD4þ cell counts below 350 cells/ml, the most cost-
effective interventions were: condom promotion, then
additionally giving short-term PrEP to HIV-negative
partners (almost doubling the number of infections
averted compared with condom promotion alone), then
switching to long-term PrEP alongside condom pro-
motion, and finally, additionally giving TasP to HIV-
positive partners. This order was well conserved across the
different parameter combinations; 61% (668/1103) gave
this same sequence. All parameter combinations
suggested condom promotion as the initial intervention,
and 90% (997/1103) suggested adding short-term PrEP
next.
For impact on DALYs, the most cost-effective initial
intervention was condom promotion, but as more
resources become available, the next most cost-effective
intervention was additionally giving TasP to HIV-positive
partners, followed by additionally giving short-term PrEP
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(Fig. 3b). For the median values, condom promotion and
the addition of TasP were incrementally highly cost-
effective at a threshold of 1 GDP [incremental cost-
effectiveness ratio (ICER) US $1206/DALY and US
$1607/DALY, respectively]. The median incremental
benefit of adding short-term PrEP to the condom
promotion and TasP interventions was cost-effective at a
threshold of 3 GDP (ICERUS $7870/DALY), but not
at 1 GDP. With more resources, a slight additional
benefit came from switching to long-term PrEP, but this
was not cost-effective (ICER US $19054/DALY). There
was substantial agreement across parameter sets: 57% gave
this same order for prioritizing interventions, with a
further 32% suggesting TasP as the most cost-effective
initial intervention, followed by condom promotion with
TasP; 99% of parameter combinations had condom
promotion with TasP on the efficiency frontier as the
second or third intervention. Using a cost-effectiveness
threshold of 1 GDP, when condom promotion was the
first indicated strategy, this was cost-effective for 741 of
742 (99%) of these parameter sets, and progressing to an
intervention with TasP and condom promotion was
incrementally cost-effective for 96% (712/742) of
parameter combinations. When TasP was the first
indicated strategy, this was cost-effective (at 1 GDP)
for 356 of 361 (99%) of parameter sets, and adding
condom promotion to TasP was cost-effective for 151/
352 (43%). Adding short-term PrEP to a condom use
with TasP strategy was only cost-effective for 1% of
parameter combinations using a 1 GDP threshold.
Using a cost-effectiveness threshold of 3GDP, condoms
with TasP (via TasP or condoms alone) was incrementally
cost-effective for 99% of parameter combinations, the
addition of short-term PrEP was cost-effective for 73%
and the subsequent switch to long-term PrEP for 6%.
At higher incidence, more infections and DALYs were
averted by each intervention (P< 0.001 for all), and the
cost per infection or DALY averted decreased (P< 0.001
for all). With higher incidence, condom promotion
(rather than TasP) was more likely to be the initial
intervention on the DALY efficiency frontier, but no
difference was seen in the order of the efficiency frontier
for infections averted.
Sensitivity analyses
Higher discount rates reduced cost-effectiveness (Fig. S2,
http://links.lww.com/QAD/A745). With the more
standard 3% annual discount rate (vs. 10%), the order
of incrementally cost-effective interventions remained
the same, but ICERs were improved (condom pro-
motion: US $590/DALY, adding TasP: US $1054/DALY,
adding short-term PrEP: US $3536/DALY, switching to
long-term PrEP: US $9259/DALY).
Increased impact and cost-effectiveness were seen over
longer time-scales (Fig. S3, http://links.lww.com/QAD/
A745). Assessing the impact over 10 rather than 20 years
changed the order of incrementally cost-effective inter-
ventions, with TasP becoming the most cost-effective
initial intervention, followed by condom promotion with
TasP (Fig. S3, http://links.lww.com/QAD/A745).
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discordant couples once their CD4R <350 cells/ml), for all
intervention combinations. Impact is measured in terms of (a)
infections averted and (b) DALYs averted. Plotted points are
medians for each intervention from 1103 parameter sets.
Intervention combinations are shown by letters and symbols
combining individual intervention elements shown in the key
(e.g. open circle with a cross through it, labelled ‘c, sp’,
indicates condom promotion þ short-term PrEP). Interven-
tions appearing on the efficiency frontier are shown in black,
with those interventions not appearing on the frontier in grey.
The solid straight lines join the medians for the incrementally
most cost-effective interventions as budget increases. In (b)
incremental additions which are highly cost-effective (incre-
mental cost per DALY averted <1 GDP) are shown by solid
lines, additions which are cost-effective (incremental cost per
DALY averted <3 GDP) are shown by dashed lines, and
additions which are not cost-effective (incremental cost per
DALY averted >3 GDP) are shown with a dotted line. ART,
antiretroviral therapy; DALYs, disability-adjusted life-years;
PrEP, pre-exposure prophylaxis.
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Assuming different initial PrEP coverage (40 or 80%
rather than 60%) made little difference to the number of
DALYs averted, but higher coverage increased total costs
(results not shown). Lower initial condom promotion
coverage (40 or 60% rather than 80%) slightly reduced
both costs and DALYs averted, and slightly reduced the
cost per DALY (results not shown). The order of
incrementally cost-effective interventions remained
the same.
Higher rates of ART re-initiation gave increased impact
for TasP, but decreased impact for PrEP and condom
promotion, and all interventions cost more per DALY
averted. With increasing ART re-initiation, TasP was
more likely to be the most cost-effective initial
intervention, followed by condom promotion, and the
addition of PrEP was less likely to be cost-effective.
Discussion
We found that offering ART to all HIV-positive partners
in serodiscordant couples in line with national treatment
guidelines would have a large effect on survival and HIV
transmission. Condom promotion for serodiscordant
couples was predicted to be highly cost-effective and
effective in reducing transmission within partnerships. In
addition, treatment as prevention – already recom-
mended by WHO for serodiscordant partnerships [28] –
was predicted to bring about substantial and highly cost-
effective additional gains in DALYs averted. Additionally
offering HIV-negative partners PrEP until their HIV-
positive partner initiated ART was also predicted to be
cost-effective (US $7870/DALY). After offering ART to
HIV-positive partners at CD4þ cell count below
350 cells/ml, offering HIV-negative partners PrEP until
their HIV-positive partner began ART was predicted to
avert 10% of remaining new HIV infections.
Despite considerable uncertainty in several model
parameters, we found consistent results for the efficiency
frontier, with condom promotion and TasP for HIV-
positive partners almost always recommended as the first
two interventions to initiate to avert DALYs, followed by
short-term PrEP for HIV-negative partners, and condom
promotion with short-term PrEP for HIV-negative
partners recommended to prevent new infections
efficiently.
The present analysis highlights the importance of condom
promotion as part of combination prevention for
serodiscordant couples – this costs the healthcare provider
relatively little, but can substantially increase condom use,
reducing the likelihood of within-couple transmission.
We allowed transmission rates amongst serodiscordant
couples to vary between two and nine new infections per
100 person-years, in the absence of Nigeria-specific
incidence estimates. We expect transmission rates
amongst serodiscordant couples in Nigeria to be some-
what lower than the higher transmission estimates (up to 9
per 100 person-years) from studies in Zambia and
Uganda, since Nigeria has higher circumcision rates [29],
and these studies were conducted in populations with
very low condom use [21], or amongst couples unaware
of their HIV status [22]. We predicted that PrEP, TasP and
condom promotion would be more cost-effective at
higher incidence, and so data on behaviour and incidence
from demonstration projects will be crucial for improving
the accuracy of cost-effectiveness estimates for Nigeria.
We predicted that very few infections (<3%) amongst
HIV-negative people in serodiscordant partnerships
would come from external partners, lower than the
estimated 20–30% in clinical trials [5,30]. This is in
agreement with previous modelling for sub-Saharan
Africa, which predicted that less than 3% of HIV
infections among serodiscordant couples would come
from external partners in countries with low (3%) HIV
prevalence [31].
In comparison with previous African cost-effectiveness
studies [12,13,32], there is less difference in our study
between the estimated annual costs of PrEP and ART; this
is likely to be because our cost estimates for PrEP and
ART include all of the same components, whereas
previous studies often took into account more com-
ponents for ART than for PrEP. A previous modelling
study of serodiscordant couples in South Africa [13]
suggested that PrEP may be more cost-effective than early
ART for the relative ratio of PrEP to ART costs and PrEP
efficacy used in our study, in couples with ‘typical’ levels
of risk. This was not found in our study, perhaps because
we assumed lower levels of unprotected sex with external
partners and a lower ratio of risk of infection from
external partners relative to stable partners, leading to
fewer infections coming from external partners. In
agreement with our findings that condom promotion and
TasP were more cost-effective than PrEP, a modelling
study of a hyper-endemic southern African setting found
that it was more cost-effective to first give early ART
before introducing PrEP [12]. Another study of
combination prevention in Kenya found that it was
usually most cost-effective to first implement behaviour
change interventions, followed by early ART, and then
PrEP [33].
We assumed a discount rate of 10% for both impacts and
costs in our baseline analysis, which led to lower estimated
cost-effectiveness than for the more standard 3% discount
rate. Although the 3% discount rate is usually recom-
mended [34], it may not reflect the willingness to trade-
off future for present consumption in Nigeria. Although
the preference for present is in theory well captured by
the interest rate, the presence of market imperfections, as
2042 AIDS 2015, Vol 29 No 15
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well as the inability of the interest rate to account for the
interest of future generations [35], justifies our decision
not to use the interest rate as a proxy for the societal
discount rate. Instead, we found evidence that preference
for present is particularly high in Nigeria since discount
rates used in Nigeria project reports varied between 8.0
and 13.7% [23–26].
We permitted a wide range of ART efficacy in our
analysis, with a preference for higher efficacies, reflecting
the fact that some observational studies have found lower
levels of transmission reduction than clinical trials [7,36].
High rates of viral suppression, between 77 and 90%
[17,37], have been reported for ART patients in Nigeria,
which compares well with the levels of viral suppression
(70% [38], 89% [5]) measured in transmission studies
which found high levels of reduction in transmission (92
and 96%, respectively). Therefore, assuming a large effect
in this setting seems reasonable.
Formative research looking at perceptions of PrEP use in
Nigeria found broad acceptability, although concerns
were raised about the impact of stigma and sustainability
of PrEP interventions [39]. The current PrEP demon-
stration project occurring among Nigerian serodiscordant
couples will give a clearer picture of PrEP feasibility, as
well as levels of condom use and ART uptake among
serodiscordant couples.
Limitations
Much of the data used to inform this analysis came from
outside Nigeria, and while HIV progression and
mortality estimates are not expected to differ greatly
between countries, there could be strain-related differ-
ences in survival and progression [40]. Most of the
behavioural data came from married people of unknown
HIV status, which may underestimate the risk behaviour
of serodiscordant couples. We did not consider second-
line ART which may have affected our ART cost
estimates. We assumed that the infectiousness of HIV-
positive individuals decreased to low levels as soon as they
started ART, with partners immediately stopping short-
term PrEP. We therefore did not evaluate the cost-
effectiveness of the more realistic scenario where HIV-
negative partners continue to take PrEP for several
months after ART initiation, while viral loads decline.
Previous modelling suggests only a small impact is
achieved over this period [13].
In conclusion, these results suggest that the best first
intervention strategy for serodiscordant couples in
Nigeria would be ensuring that all HIV-positive partners
are offered ARTat current national guidelines. Additional
reduction in new infections could be achieved by
promoting condom use amongst serodiscordant couples,
and offering PrEP to HIV-negative partners until their
HIV-positive partner initiates ART. Additional DALYs
could be averted through condom promotion for couples
and TasP for HIV-positive partners, which would both be
incrementally highly cost-effective, followed by offering
PrEP to HIV-negative partners until their HIV-positive
partner initiates ART.
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